Joel Lelievre

Global Health R&D
Tres Cantos, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis.

Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis.

Journal: Microbiology (Reading, England)

Published: February 07, 2023

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.

Journal: Antimicrobial agents and chemotherapy

Published: January 23, 2023

GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

Journal: Antimicrobial agents and chemotherapy

Published: May 24, 2022

A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.

A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.

Journal: Antimicrobial agents and chemotherapy

Published: October 04, 2021

The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation.

The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation.

Journal: Cell surface (Amsterdam, Netherlands)

Published: September 08, 2021

The Tuberculosis Drug Accelerator at year 10: what have we learned?

The Tuberculosis Drug Accelerator at year 10: what have we learned?

Journal: Nature medicine

Published: July 06, 2021

A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity.

A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity.

Journal: Antimicrobial agents and chemotherapy

Published: February 09, 2021

Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.

Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.

Journal: Antimicrobial agents and chemotherapy

Published: September 04, 2020

Development of a novel secondary phenotypic screen to identify hits within the mycobacterial protein synthesis pipeline.

Development of a novel secondary phenotypic screen to identify hits within the mycobacterial protein synthesis pipeline.

Journal: FASEB bioAdvances

Published: April 17, 2020

Development of a whole-cell high-throughput phenotypic screen to identify inhibitors of mycobacterial amino acid biosynthesis.

Development of a whole-cell high-throughput phenotypic screen to identify inhibitors of mycobacterial amino acid biosynthesis.

Journal: FASEB bioAdvances

Published: November 05, 2018

Development of high throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis.

Development of high throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis.

Journal: Analytical biochemistry

Published: October 27, 2018

Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach.

Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach.

Journal: Scientific reports

Published: June 11, 2018

Showing 1-12 of 34

Last Updated: 09/26/2026